TARC schedules board meeting

Mumbai, Oct. 31 -- TARC will hold a meeting of the Board of Directors of the Company on 5 November 2026. Published by HT Digital Content Services with permission from Capital Market.... Read More

Tracxn Techs. to convene board meeting

Mumbai, Oct. 31 -- Tracxn Techs. will hold a meeting of the Board of Directors of the Company on 4 November 2026. Published by HT Digital Content Services with permission from Capital Market.... Read More

Pix Transmission announces board meeting date

Mumbai, Oct. 31 -- Pix Transmission will hold a meeting of the Board of Directors of the Company on 6 November 2026. Published by HT Digital Content Services with permission from Capital Market.... Read More

Singapore Clinical Trial: A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Tersolisib (LY4064809) Combined with a CDK4/6 Inhibitor and Endocrine Therapy in Adults with HR+, HER2- Advanced Breast Cancer with a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)

Singapore, Oct. 31 -- The Health Sciences Authority received information related to the study titled 'A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo... Read More

Singapore Clinical Trial: A Phase 1 Open-Label Study to Determine the Effect of Injection Site on the Relative Bioavailability of a Single Subcutaneous Dose of LY3841136 and to Evaluate the Pharmacokinetics of a Single Intravenous Dose of LY3841136 in Healthy Participants.

Singapore, Oct. 31 -- The Health Sciences Authority received information related to the study titled 'A Phase 1 Open-Label Study to Determine the Effect of Injection Site on the Relative Bioavailabili... Read More

Singapore Clinical Trial: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine (MK-5884) Versus Placebo for the Prevention of COPD Exacerbations in Adults with a History of Moderate or Severe Exacerbations While Receiving Standard of Care (ENHANCE-3)

Singapore, Oct. 31 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety ... Read More

Singapore Clinical Trial: A Phase 1, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4174794 in Participants with Obesity or Overweight who are Otherwise Healthy

Singapore, Oct. 31 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose-Escalation Study to ... Read More

Singapore Clinical Trial: A Phase 2 Platform Basket Study Evaluating Advanced Therapies in Subjects with Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

Singapore, Oct. 31 -- The Health Sciences Authority received information related to the study titled 'A Phase 2 Platform Basket Study Evaluating Advanced Therapies in Subjects with Moderately to Sever... Read More

Singapore Clinical Trial: A Phase 3, Randomized, Open-Label Study of Rinzimetostat (ORIC-944) in Combination with Darolutamide Compared with ARPI or Docetaxel in Patients with Metastatic Castration Resistant Prostate Cancer Previously Treated with Abiraterone Acetate (Himalayas-1)

Singapore, Oct. 31 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-Label Study of Rinzimetostat (ORIC-944) in Combination with Darolutami... Read More

Singapore Clinical Trial: A Phase 3, Randomized, Open-Label Study of Rinzimetostat (ORIC-944) in Combination with Darolutamide Compared with ARPI or Docetaxel in Patients with Metastatic Castration Resistant Prostate Cancer Previously Treated with Abiraterone Acetate (Himalayas-1)

Singapore, Oct. 31 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-Label Study of Rinzimetostat (ORIC-944) in Combination with Darolutami... Read More

• ««
• «
• 1415
• 1416
• 1417
• 1418
• 1419
• 1420
• 1421
• 1422
• 1423
• 1424
• »
• »»